首页 | 本学科首页   官方微博 | 高级检索  
     


PGC-1s in the Spotlight with Parkinson’s Disease
Authors:Elena Piccinin  Anna Maria Sardanelli  Peter Seibel  Antonio Moschetta  Tiziana Cocco  Gaetano Villani
Affiliation:1.Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari “Aldo Moro”, 70124 Bari, Italy; (E.P.); (A.M.S.);2.Department of Medicine, University Campus Bio-Medico of Rome, 00128 Rome, Italy;3.Molecular Cell Therapy, BBZ, Medical Faculty, University of Leipzig, Deutscher Platz 5, 04103 Leipzig, Germany;4.Department of Interdisciplinary Medicine, University of Bari “Aldo Moro”, 70124 Bari, Italy;
Abstract:Parkinson’s disease is one of the most common neurodegenerative disorders worldwide, characterized by a progressive loss of dopaminergic neurons mainly localized in the substantia nigra pars compacta. In recent years, the detailed analyses of both genetic and idiopathic forms of the disease have led to a better understanding of the molecular and cellular pathways involved in PD, pointing to the centrality of mitochondrial dysfunctions in the pathogenic process. Failure of mitochondrial quality control is now considered a hallmark of the disease. The peroxisome proliferator-activated receptor gamma coactivator 1 (PGC-1) family acts as a master regulator of mitochondrial biogenesis. Therefore, keeping PGC-1 level in a proper range is fundamental to guarantee functional neurons. Here we review the major findings that tightly bond PD and PGC-1s, raising important points that might lead to future investigations.
Keywords:PGC-1, coactivators, neurodegenerative disease, Parkinson’  s disease, mitochondria
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号